Alex Badamchi-Zadeh, PhD is a Biotech Investor at SV Health Investors in London, where he has invested since 2020 across four SV funds (SV6, SV7 IMF, SV BCOF, SV8). He has been involved in over 25 financings and in exits including EyeBio (acquired by Merck for $3b, 2024) and Nimbus Therapeutics (acquired by Takeda for $6b, 2022), as well as the IPO of BioAge Labs (NASDAQ: BIOA). The EyeBio transaction earned recognition as M&A Deal of the Year in 2024.
Alex’s active portfolio includes Serenza Therapeutics (Director), Alchemab Therapeutics (Observer), Dualitas Therapeutics (Observer), Altimis Bio, Merge Therapeutics, Nimbus Therapeutics & Sitryx; and has managed investments in EyeBio (Observer), Therini Bio (Observer), Catamaran Bio (Observer), Ribometrix, TRex Bio and X4 Pharma. He also sits on the Investment Committee of Cancer Research Horizons Fund, the innovation arm of Cancer Research UK, since its creation in 2022.
Before SV, Alex led business development and strategy at Xilio Therapeutics, including its $100.5M Series B, and advised biopharma clients as a life sciences consultant at L.E.K. Consulting. He began his career as an immunologist, completing a postdoctoral fellowship at Harvard Medical School (Dan Barouch Lab), where he contributed to vaccine and immunotherapeutic research and has published over 20 publications including in Nature, Science Immunology and others.
Academic Credentials
Alex received his MRes and PhD in Medicine (Immunology) from Imperial College London, and holds a BA (Hons) in Biological Sciences from Christ Church, University of Oxford.
